about
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusThe cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.Clinical trial participation after myocardial infarction in a national cardiovascular data registry.The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services.Anticoagulation after anterior myocardial infarction and the risk of stroke.Does this patient with liver disease have cirrhosis?Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseComparable benefit of β-blocker therapy in heart failure across regions of the world: meta-analysis of randomized clinical trials.Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled TrialsPrimary and secondary prevention of heart failure with statins.Lipid-lowering therapy and outcomes in heart failure.Inequitable distribution of implantable cardioverter defibrillators in Ontario.Failure of fertility therapy and subsequent adverse cardiovascular events.Regional variations in ambulatory care and incidence of cardiovascular events.Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.Patent foramen ovale closure vs medical therapy for stroke prevention: meta-analysis of randomized trials and review of heterogeneity in meta-analyses.Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial.Design and methods of the Echo WISELY (Will Inappropriate Scenarios for Echocardiography Lessen SignificantlY) study: An investigator-blinded randomized controlled trial of education and feedback intervention to reduce inappropriate echocardiograms.Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.Cardiovascular Risk Following Fertility Therapy: Systematic Review and Meta-Analysis.Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial.Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.Antiarrhythmic therapy as an adjuvant to promote post pulmonary vein isolation success-a meta-analysis.Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes.Cardiovascular Risk Factor Management Performance in Canada and the United States: A Systematic Review.Respiratory Tract Infections, Nonsteroidal Anti-inflammatory Drugs and Acute Myocardial Infarction: Is Understanding Interaction Between Risk Factors the Key to Personalizing Prevention?A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid.Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome.Does influenza vaccination influence cardiovascular complications?Clinical Characteristics, Management, and Outcomes of Acute Coronary Syndrome in Patients With Right Bundle Branch Block on Presentation.Outcomes of Women and Men With Acute Coronary Syndrome Treated With and Without Percutaneous Coronary Revascularization.Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infMetabolic syndrome, diabetes mellitus, or both and cardiovascular risk in outpatients with or at risk for atherothrombosis.The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study.
P50
Q28297680-ED197F4E-A97A-4196-9488-62A709701F47Q30235290-6B5A9E64-6D74-4DC3-BD9D-3640CC2CFE3AQ30844989-6EAB53D3-BF89-49D9-9520-FE05CBD68A06Q30887359-96202C37-A9FB-40FC-9FE9-1A39E1A28392Q33668758-57CF1328-CCEE-42A5-8D54-6B5A027A7D73Q34256389-056A8B6A-C0C2-456E-91C0-530E39CC7E88Q34379610-B6CA866A-DE00-4644-A45A-743D391EF02BQ34421217-8942155C-1959-45A5-9DBE-127E6325A213Q35190073-C26B6A74-ACBA-4997-A354-FEDB93457EE5Q35581749-61F5AB7F-1525-4D3A-8819-D09DC9F90D6AQ36141300-AAEE1739-A679-4C04-BAC9-3007F0012786Q36686069-62615CC1-879C-49B5-817E-9FC55D66506BQ36818242-E4CAC0A1-F4A3-4024-B9AD-593ED8C7B300Q36853736-54DEBB51-4270-451B-99C4-87103B9E6ACCQ37712334-BEB952DD-EB31-45CC-8DB3-D6D02C01920AQ37735860-A34EF78B-98B9-4856-8378-5D7D27E59A24Q38023765-EF447756-73DF-4F8B-8163-F8D0721E146DQ38243012-2E276F04-49A6-4E80-A654-C25EC1F4AD60Q38387073-CE2555D4-3E7A-41EC-9FF4-6933B6207BF4Q38405445-D65EFB32-B483-4757-B8F7-82EF17020B54Q38424163-9AA7C683-0ABC-40AD-93F7-08FBEAE7ED3BQ38577755-487CD7C1-8448-4A97-BA22-29797D8BC044Q38599376-6D8530B7-2208-4053-BA91-D9937B87403BQ38611678-7EEF7FFA-DD9D-497E-873C-0FC51B4C62A5Q38842742-12C76512-927D-42A4-A0CB-FE61BC5EE4B5Q38880992-24731DE6-5F6D-449E-85AA-E2035FE1BC9CQ38960765-EEA2664B-EA5B-45E3-A356-DDE29CBD9392Q39016973-87140166-8478-4257-870A-5F8A293B4FF3Q39579526-F9304A55-4FEB-4D28-BC66-740A478B1D18Q39894376-D28B4BF7-47C4-4394-8153-141275BDD8C0Q40128080-EAA4A085-E60C-4030-942C-8FFD617908AAQ40320888-39E3FEBC-2315-4303-95C6-E98524E9C925Q40782914-E377BD64-D8F5-465C-ABB8-0B909E6A7D2AQ40942336-F5557070-FB0E-4A9E-ABCF-4B2A37C1FE53Q40980493-2A9039EF-E86B-4745-8DD9-0CA25DD748C8Q41101718-E170E4EB-E192-4080-9D2A-F6CE5849A6E0Q41634829-213817C2-0F44-4532-BAC9-0BF792260545Q43459231-ECEEEAC6-A039-4E56-A6CC-DB28A97AC0A5Q44655760-D04315F7-68F2-4B8D-BEA4-BC1F3528F054Q45105400-6CAD232F-7A8E-4D26-B5B3-21BC571BAE76
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jacob A Udell
@nl
Jacob A Udell
@sl
Jacob A. Udell
@en
Jacob A. Udell
@es
type
label
Jacob A Udell
@nl
Jacob A Udell
@sl
Jacob A. Udell
@en
Jacob A. Udell
@es
prefLabel
Jacob A Udell
@nl
Jacob A Udell
@sl
Jacob A. Udell
@en
Jacob A. Udell
@es
P106
P1153
13204748500
P21
P31
P496
0000-0001-7402-9584